GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medincell SA (XPAR:MEDCL) » Definitions » Beneish M-Score

Medincell (XPAR:MEDCL) Beneish M-Score : -4.00 (As of Dec. 11, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Medincell Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -4 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Medincell's Beneish M-Score or its related term are showing as below:

XPAR:MEDCL' s Beneish M-Score Range Over the Past 10 Years
Min: -4.34   Med: -2.97   Max: 9.61
Current: -4

During the past 9 years, the highest Beneish M-Score of Medincell was 9.61. The lowest was -4.34. And the median was -2.97.


Medincell Beneish M-Score Historical Data

The historical data trend for Medincell's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medincell Beneish M-Score Chart

Medincell Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only -3.79 -2.15 -2.56 -2.97 -4.00

Medincell Semi-Annual Data
Mar16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -2.97 - -4.00 -

Competitive Comparison of Medincell's Beneish M-Score

For the Biotechnology subindustry, Medincell's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medincell's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medincell's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Medincell's Beneish M-Score falls into.



Medincell Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Medincell for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.19+0.528 * 0.986+0.404 * 0.9946+0.892 * 0.9083+0.115 * 0.8619
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1+4.679 * -0.354985-0.327 * 0.7465
=-3.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was €2.27 Mil.
Revenue was €9.03 Mil.
Gross Profit was €9.16 Mil.
Total Current Assets was €27.26 Mil.
Total Assets was €36.95 Mil.
Property, Plant and Equipment(Net PPE) was €5.43 Mil.
Depreciation, Depletion and Amortization(DDA) was €1.72 Mil.
Selling, General, & Admin. Expense(SGA) was €11.81 Mil.
Total Current Liabilities was €16.47 Mil.
Long-Term Debt & Capital Lease Obligation was €50.54 Mil.
Net Income was €-25.04 Mil.
Gross Profit was €0.00 Mil.
Cash Flow from Operations was €-11.92 Mil.
Total Receivables was €2.10 Mil.
Revenue was €9.94 Mil.
Gross Profit was €9.94 Mil.
Total Current Assets was €19.57 Mil.
Total Assets was €29.34 Mil.
Property, Plant and Equipment(Net PPE) was €6.37 Mil.
Depreciation, Depletion and Amortization(DDA) was €1.67 Mil.
Selling, General, & Admin. Expense(SGA) was €0.00 Mil.
Total Current Liabilities was €57.03 Mil.
Long-Term Debt & Capital Lease Obligation was €14.25 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(2.273 / 9.032) / (2.103 / 9.944)
=0.251661 / 0.211484
=1.19

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(9.944 / 9.944) / (9.16 / 9.032)
=1 / 1.014172
=0.986

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (27.258 + 5.434) / 36.948) / (1 - (19.568 + 6.373) / 29.339)
=0.115189 / 0.115819
=0.9946

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=9.032 / 9.944
=0.9083

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.665 / (1.665 + 6.373)) / (1.719 / (1.719 + 5.434))
=0.207141 / 0.240319
=0.8619

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(11.809 / 9.032) / (0 / 9.944)
=1.307462 / 0
=1

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((50.541 + 16.466) / 36.948) / ((14.252 + 57.025) / 29.339)
=1.813549 / 2.429428
=0.7465

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-25.038 - 0 - -11.922) / 36.948
=-0.354985

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Medincell has a M-score of -3.99 suggests that the company is unlikely to be a manipulator.


Medincell Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Medincell's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Medincell Business Description

Traded in Other Exchanges
Address
3 rue des Freres Lumiere, Jacou, FRA, 34830
Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.

Medincell Headlines

No Headlines